KDR and neoplasm: Although there is evidence that bevacizumab reduces tumor edema, angiogenesis, and disease burden, the use of this agent as well as other VEGF/VEGFR-targeting drugs has been followed by resistance (largely as a result of adaptive tumor responses) in preclinical models and in clinical settings.